The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling

  1. Amy A Worth
  2. Rosemary Shoop
  3. Katie Tye
  4. Claire H Feetham
  5. Giuseppe D'Agostino
  6. Garron T Dodd
  7. Frank Reimann
  8. Fiona M Gribble
  9. Emily C Beebe
  10. James D Dunbar
  11. Jesline T Alexander-Chacko
  12. Dana K Sindelar
  13. Tamer Coskun
  14. Paul J Emmerson
  15. Simon M Luckman  Is a corresponding author
  1. University of Manchester, United Kingdom
  2. University of Melbourne, Australia
  3. University of Cambridge, United Kingdom
  4. Eli Lilly and Company, United States

Abstract

The cytokine, GDF15, is produced in pathological states which cause cellular stress, including cancer. When over expressed, it causes dramatic weight reduction, suggesting a role in disease-related anorexia. Here we demonstrate that the GDF15 receptor, GFRAL, is located in a subset of cholecystokinin neurons which span the area postrema and the nucleus of the tractus solitarius of the mouse. GDF15 activates GFRALAP/NTS neurons and supports conditioned taste and place aversions, while the anorexia it causes can be blocked by a monoclonal antibody directed at GFRAL or by disrupting CCK neuronal signalling. The cancer-therapeutic drug, cisplatin, induces the release of GDF15 and activates GFRALAP/NTS neurons, as well as causing significant reductions in food intake and body weight in mice. These metabolic effects of cisplatin are abolished by pre-treatment with the GFRAL monoclonal antibody. Our results suggest that GFRAL neutralising antibodies or antagonists may provide a co-treatment opportunity for patients undergoing chemotherapy.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Amy A Worth

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  2. Rosemary Shoop

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3617-4358
  3. Katie Tye

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  4. Claire H Feetham

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  5. Giuseppe D'Agostino

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    Competing interests
    No competing interests declared.
  6. Garron T Dodd

    Department of Physiology, University of Melbourne, Melbourne, Australia
    Competing interests
    No competing interests declared.
  7. Frank Reimann

    Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.
  8. Fiona M Gribble

    Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    No competing interests declared.
  9. Emily C Beebe

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Emily C Beebe, Paid employee of Eli Lilly..
  10. James D Dunbar

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    James D Dunbar, Paid employee of Eli Lilly..
  11. Jesline T Alexander-Chacko

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Jesline T Alexander-Chacko, Paid employee of Eli Lilly..
  12. Dana K Sindelar

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Dana K Sindelar, Paid employee of Eli Lilly..
  13. Tamer Coskun

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Tamer Coskun, Paid employee of Eli Lilly..
  14. Paul J Emmerson

    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Paul J Emmerson, Paid employee of Eli Lilly..
  15. Simon M Luckman

    Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
    For correspondence
    simon.luckman@manchester.ac.uk
    Competing interests
    Simon M Luckman, BB/S008098/1 is a BBSRC Industrial Partnership Award between SML and Eli Lilly.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5318-5473

Funding

Biotechnology and Biological Sciences Research Council (BB/M001067/1)

  • Simon M Luckman

Biotechnology and Biological Sciences Research Council (BB/L021129/1)

  • Simon M Luckman

Medical Research Council (MR/R002991/1)

  • Simon M Luckman

Medical Research Council (MR/P009824/2)

  • Giuseppe D'Agostino

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Richard D Palmiter, Howard Hughes Medical Institute, University of Washington, United States

Ethics

Animal experimentation: All procedures were conducted in accordance with either: the United Kingdom Animals (Scientific Procedures) Act, 1986 (ASPA) and approved by the local animal welfare ethical review body (AWERB); the Eli Lilly Institutional Animal Care and Use Committee (IACUC) in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals; or the University of Melbourne Animal Ethics Committee (1914919) and conformed to National Health & 8 Medical Research Council (Australia) guidelines regarding the care and use of experimental animals. Additional guidance from the UK National Centre for 3R's (NC3Rs) was followed where applicable.

Version history

  1. Received: January 14, 2020
  2. Accepted: July 26, 2020
  3. Accepted Manuscript published: July 29, 2020 (version 1)
  4. Version of Record published: August 6, 2020 (version 2)

Copyright

© 2020, Worth et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,817
    Page views
  • 631
    Downloads
  • 42
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Amy A Worth
  2. Rosemary Shoop
  3. Katie Tye
  4. Claire H Feetham
  5. Giuseppe D'Agostino
  6. Garron T Dodd
  7. Frank Reimann
  8. Fiona M Gribble
  9. Emily C Beebe
  10. James D Dunbar
  11. Jesline T Alexander-Chacko
  12. Dana K Sindelar
  13. Tamer Coskun
  14. Paul J Emmerson
  15. Simon M Luckman
(2020)
The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling
eLife 9:e55164.
https://doi.org/10.7554/eLife.55164

Share this article

https://doi.org/10.7554/eLife.55164

Further reading

    1. Developmental Biology
    2. Neuroscience
    Tariq Zaman, Daniel Vogt ... Michael R Williams
    Research Article

    The cell-type-specific expression of ligand/receptor and cell-adhesion molecules is a fundamental mechanism through which neurons regulate connectivity. Here, we determine a functional relevance of the long-established mutually exclusive expression of the receptor tyrosine kinase Kit and the trans-membrane protein Kit Ligand by discrete populations of neurons in the mammalian brain. Kit is enriched in molecular layer interneurons (MLIs) of the cerebellar cortex (i.e., stellate and basket cells), while cerebellar Kit Ligand is selectively expressed by a target of their inhibition, Purkinje cells (PCs). By in vivo genetic manipulation spanning embryonic development through adulthood, we demonstrate that PC Kit Ligand and MLI Kit are required for, and capable of driving changes in, the inhibition of PCs. Collectively, these works in mice demonstrate that the Kit Ligand/Kit receptor dyad sustains mammalian central synapse function and suggest a rationale for the affiliation of Kit mutation with neurodevelopmental disorders.

    1. Neuroscience
    Hideo Hagihara, Hirotaka Shoji ... Tsuyoshi Miyakawa
    Research Article

    Increased levels of lactate, an end-product of glycolysis, have been proposed as a potential surrogate marker for metabolic changes during neuronal excitation. These changes in lactate levels can result in decreased brain pH, which has been implicated in patients with various neuropsychiatric disorders. We previously demonstrated that such alterations are commonly observed in five mouse models of schizophrenia, bipolar disorder, and autism, suggesting a shared endophenotype among these disorders rather than mere artifacts due to medications or agonal state. However, there is still limited research on this phenomenon in animal models, leaving its generality across other disease animal models uncertain. Moreover, the association between changes in brain lactate levels and specific behavioral abnormalities remains unclear. To address these gaps, the International Brain pH Project Consortium investigated brain pH and lactate levels in 109 strains/conditions of 2294 animals with genetic and other experimental manipulations relevant to neuropsychiatric disorders. Systematic analysis revealed that decreased brain pH and increased lactate levels were common features observed in multiple models of depression, epilepsy, Alzheimer’s disease, and some additional schizophrenia models. While certain autism models also exhibited decreased pH and increased lactate levels, others showed the opposite pattern, potentially reflecting subpopulations within the autism spectrum. Furthermore, utilizing large-scale behavioral test battery, a multivariate cross-validated prediction analysis demonstrated that poor working memory performance was predominantly associated with increased brain lactate levels. Importantly, this association was confirmed in an independent cohort of animal models. Collectively, these findings suggest that altered brain pH and lactate levels, which could be attributed to dysregulated excitation/inhibition balance, may serve as transdiagnostic endophenotypes of debilitating neuropsychiatric disorders characterized by cognitive impairment, irrespective of their beneficial or detrimental nature.